Impact of IL-10 Gene Promoter Polymorphisms on Treatment Response in HCV Patients: A Systematic Review, a Meta-analysis, and a Meta-regression

Overview

Journal Int J Immunopathol Pharmacol

Publisher Sage Publications

Specialties Allergy & Immunology
Pathology
Pharmacology

Date 2024 Mar 23

PMID 38520313

Authors

Tarak Dhaouadi

Awatef Riahi

Taieb Ben Abdallah

Yousr Gorgi

Imen Sfar

Affiliations

Soon will be listed here.

Abstract

The impact of interleukin-10 (IL-10) gene promoter polymorphisms (SNPs) on treatment response in HCV patients was dissimilarly estimated. Hence, the aim of this meta-analysis was to robustly assess the effect of IL-10 SNPs on treatment response in HCV patients. An electronic literature search was carried out through PubMed, EMBASE, Web of science, and Scopus databases. Studies assessing the association between IL-10 polymorphisms and treatment response in HCV patients were included. Studies were excluded if genotype frequencies are not consistent with the Hardy-Weinberg Equilibrium (HWE) or in case of including patients with hepatitis B virus coinfection. Risk of bias in included studies was assessed using the Newcastle-Ottawa Scale. Meta-analyses were performed for the influence of IL-10 gene promoter SNPs (rs1800896 (-1082 A/G), rs1800871 (-819 C/T), and rs1800872 (-592 C/T)) and haplotypes on treatment response in HCV patients. Subgroup analyses, meta-regressions, publication bias assessment, and sensitivity analyses were also conducted. Overall, 32 studies with a total of 5943 HCV cases and 2697 controls were included in the present study. The -1082*G allele was significantly associated with increased risk of non-response (NR) to treatment, OR [95% CI] = 1.29 [1.1-1.51], = .002. Besides, the rs1800872 -592*C allele was significantly associated with increased NR risk, OR [95% CI] = 1.22 [1.02-1.46], = .03. Subgroup analysis showed that this association remained significant only in patients treated with PEG-IFN alone, = .01. The -1082*G/-819*C/-592*C (GCC) haplotype was significantly associated with increased NR risk, OR [95% CI] = 1.62 [1.13-2.23], = .009. Our results suggest that the IL-10 rs1800896 was associated with NR risk especially in North-African and Asian populations. Moreover, the IL-10 gene promoter -1082*G/-819*C/-592*C (GCC) haplotype which has been associated with higher production of IL-10, was significantly associated with increased NR risk.

References

Corchado S, Lopez-Cortes L, Rivero-Juarez A, Torres-Cornejo A, Rivero A, Marquez-Coello M . Liver fibrosis, host genetic and hepatitis C virus related parameters as predictive factors of response to therapy against hepatitis C virus in HIV/HCV coinfected patients. PLoS One. 2014; 9(7):e101760. PMC: 4094489. DOI: 10.1371/journal.pone.0101760. View

Rao H, Sun D, Jiang D, Yang R, Guo F, Wang J . IL28B genetic variants and gender are associated with spontaneous clearance of hepatitis C virus infection. J Viral Hepat. 2012; 19(3):173-81. DOI: 10.1111/j.1365-2893.2011.01497.x. View

Chuang J, Yang S, Lu Y, Hsieh Y, Chen C, Chang S . IL-10 promoter gene polymorphisms and sustained response to combination therapy in Taiwanese chronic hepatitis C patients. Dig Liver Dis. 2008; 41(6):424-30. DOI: 10.1016/j.dld.2008.09.017. View

Junaid K, Rasool H, Ul Mustafa A, Ejaz H, Alsrhani A, Yasmeen H . Association of IL28 B and IL10 Polymorphism with HCV Infection and Direct Antiviral Treatment. Ann Clin Lab Sci. 2021; 51(4):512-520. View

Di Marco V, Covolo L, Calvaruso V, Levrero M, Puoti M, Suter F . Who is more likely to respond to dual treatment with pegylated-interferon and ribavirin for chronic hepatitis C? A gender-oriented analysis. J Viral Hepat. 2013; 20(11):790-800. DOI: 10.1111/jvh.12106. View

Trikalinos T, Salanti G, Khoury M, Ioannidis J . Impact of violations and deviations in Hardy-Weinberg equilibrium on postulated gene-disease associations. Am J Epidemiol. 2006; 163(4):300-9. DOI: 10.1093/aje/kwj046. View

Walter M . The molecular basis of IL-10 function: from receptor structure to the onset of signaling. Curr Top Microbiol Immunol. 2014; 380:191-212. PMC: 4489423. DOI: 10.1007/978-3-662-43492-5_9. View

Shaker O, Nassar Y, Nour Z, El Raziky M . Single-nucleotide polymorphisms of IL-10 and IL-28B as predictors of the response of IFN therapy in HCV genotype 4-infected children. J Pediatr Gastroenterol Nutr. 2013; 57(2):155-60. DOI: 10.1097/MPG.0b013e31828febf0. View

Khan A, Saraswat V, Choudhuri G, Parmar D, Negi T, Mohindra S . Association of interleukin-10 polymorphisms with chronic hepatitis C virus infection in a case-control study and its effect on the response to combined pegylated interferon/ribavirin therapy. Epidemiol Infect. 2014; 143(1):71-80. PMC: 9206795. DOI: 10.1017/S0950268814000466. View

10.

Mangia A, Santoro R, Piattelli M, Pazienza V, Grifa G, Iacobellis A . IL-10 haplotypes as possible predictors of spontaneous clearance of HCV infection. Cytokine. 2003; 25(3):103-9. DOI: 10.1016/j.cyto.2003.10.005. View

11.

Abdelraheem W, Hassuna N, Abuloyoun S, Abdel Ghany H, Rizk H, Abdelwahab S . Interleukin-10.rs1800896 and Interleukin-18.rs1946518 gene polymorphisms could not predict the outcome of hepatitis C virus infection in Egyptian patients treated with pegylated interferon plus ribavirin. Arch Virol. 2016; 161(9):2473-80. DOI: 10.1007/s00705-016-2948-y. View

12.

Naeemi H, Aslam R, Raza S, Aiman Shahzad M, Naz S, Manzoor S . Distribution of IL28B and IL10 polymorphisms as genetic predictors of treatment response in Pakistani HCV genotype 3 patients. Arch Virol. 2018; 163(4):997-1008. DOI: 10.1007/s00705-018-3711-3. View

13.

Paladino N, Fainboim H, Theiler G, Schroder T, Munoz A, Flores A . Gender susceptibility to chronic hepatitis C virus infection associated with interleukin 10 promoter polymorphism. J Virol. 2006; 80(18):9144-50. PMC: 1563933. DOI: 10.1128/JVI.00339-06. View

14.

Lima de Souza S, Vidal L, Ramos J, Cardoso C, Coelho H, Villela-Nogueira C . Hepatitis C Virus-Infected Responders and Relapsers to Treatment Show Similar Genetic Profiles of and Single Nucleotide Polymorphisms. Biomed Res Int. 2018; 2018:2931486. PMC: 5985065. DOI: 10.1155/2018/2931486. View

15.

Shaker O, Abdel-Rahim M, Bayoumi S . Gene polymorphisms of IL-10 and MxA in responders and non-responders to interferon therapy in HCV Egyptian patients genotype 4. Cell Biochem Biophys. 2014; 71(2):617-25. DOI: 10.1007/s12013-014-0241-9. View

16.

Yew K, Tan Q, Lim P, Low W, Lee C . Assessing the impact of direct-acting antivirals on hepatitis C complications: a systematic review and meta-analysis. Naunyn Schmiedebergs Arch Pharmacol. 2023; 397(3):1421-1431. DOI: 10.1007/s00210-023-02716-x. View

17.

Pasha H, Radwan M, Hagrass H, Tantawy E, Emara M . Cytokines genes polymorphisms in chronic hepatitis C: impact on susceptibility to infection and response to therapy. Cytokine. 2012; 61(2):478-84. DOI: 10.1016/j.cyto.2012.11.003. View

18.

Grandi T, da Silva C, Amaral K, Picon P, Costi C, Fre N . Tumour necrosis factor -308 and -238 promoter polymorphisms are predictors of a null virological response in the treatment of Brazilian hepatitis C patients. Mem Inst Oswaldo Cruz. 2014; 109(3):345-51. PMC: 4131788. DOI: 10.1590/0074-0276130372. View

19.

Jonsson J, Purdie D, Bansal A, Shorthouse C, Powell E . Interleukin-10 promoter polymorphism predicts initial response of chronic hepatitis C to interferon alfa. Hepatology. 1999; 30(2):526-30. DOI: 10.1002/hep.510300207. View

20.

Berry L, Irving W . Predictors of hepatitis C treatment response: what's new?. Expert Rev Anti Infect Ther. 2014; 12(2):183-91. DOI: 10.1586/14787210.2014.874283. View